

The good and the bad: strategical considerations before stage I

Damien Bonnet

Service de Cardiologie Congénitale et Pédiatrique
Hôpital Universitaire Necker Enfants malades – APHP

Université de Paris Cité

INSERM-U781 - Institut Hospitalo-Universitaire IMAGINE

Centre de Référence Maladies Rares

Malformations Cardiaques Congénitales Complexes-M3C

Centre de Référence Maladies Rares

Maladies Cardiaques Héritaires- CARDIOGEN



Definition of a strategy:

« a plan of action designed to achieve a long-term aim »



The plan of action may change at different time points

	Fetus	Neonate	Infant	Child & beyond
Survival	Termination of pregnancy Planned delivery	Comfort care	Comfort care	Comfort care
Interventions	Aortic valve dilatation Atrial septum opening	Preoperative care Stage 1 palliation Transplantation	Stage 2 palliation Transplantation	Stage 3 palliation Transplantation
Suitability for subsequent stage	NA	Suitability fo stage 2	Suitability for TCPC	Suitability for transplantation

The plan of action may change at different time points

	Fetus	Neonate	Infant	Child & beyond
Survival	Termination of pregnancy Planned delivery	Comfort care	Comfort care	Comfort care
Interventions	Aortic valve dilatation Atrial septum opening	Preoperative care Stage 1 palliation Transplantation	Stage 2 palliation Transplantation	Stage 3 palliation Transplantation
Suitability for subsequent stage	NA	Suitability fo stage 2	Suitability for TCPC	Suitability for transplantation


The plan of action may change at different time points

	Fetus	Neonate	Infant	Child & beyond
Survival	Termination of pregnancy Planned delivery	Comfort care	Comfort care	Comfort care
Interventions	Aortic valve dilatation Atrial septum opening	Preoperative care Stage 1 palliation Transplantation	Stage 2 palliation Transplantation	Stage 3 palliation Transplantation
Suitability for subsequent stage	NA	Suitability fo stage 2	Suitability for TCPC	Suitability for transplantation

The plan of action may change at different time points


	Fetus	Neonate	Infant	Child & beyond
Survival	Termination of pregnancy Planned delivery	Comfort care	Comfort care	Comfort care
Interventions	Aortic valve dilatation Atrial septum opening	Preoperative care Stage 1 palliation Transplantation	Stage 2 palliation Transplantation	Stage 3 palliation Transplantation
Suitability for subsequent stage	NA	Suitability fo stage 2	Suitability for TCPC	Suitability for transplantation


Hypoplastic left heart syndrome/HLH complex




Is it possible stratify risk in HLHS before stage 1 ?

- **The current goal of HLHS management before stage 1 is to identify the factors associated with the achievement initial objectives of stage 1 palliation that are:**
 1. Provide unobstructed systemic cardiac output;
 2. Provide a controlled source of pulmonary blood flow;
 3. Provide a reliable source of coronary blood flow;
 4. Provide unobstructed egress of blood from the pulmonary veins.
- **To achieve a low-mortality/adverse events-risk status** during postoperative course and during interstage period.
- To enable this outcome, **assessments of mortality/adverse events risk factors** should be made **at diagnosis and during pre-Stage 1palliation period** with appropriate tools.
- **The results of these assessments should be used to guide preoperative medical management and surgical strategy.**
- Finally, these assessments should lead to a proactive change in therapy according to risk status.








Evaluation and management of life-maintaining structures



Atrial septum




1. **Type A atrial morphology.** A relatively large left atrium with a thick septum secundum and a thin septum primum adherent to each other. Frequent leftward and posteriorly deviated septum primum attached to the roof of the left atrium.
2. **Type B atrial morphology.** A small, muscular left atrium with circumferential thickening of the atrial walls and a thick “spongy” muscular atrial septum without ostensible distinction between septum primum and septum secundum.
3. **Type C atrial morphology.** A giant left atrium with a thin, rightward bulging, septum primum and secundum, this in the setting of severe mitral regurgitation


Evaluation and management of life-maintaining structures

Atrial septum with decompression pathway




Levo-cardio-atrial vein (Levocardinal vein)






Patent Foramen ovale



Intact-restrictive Foramen ovale



Atrial septal characteristics distinguishing Standard atrial septal anatomy (group A) from Complex atrial septal anatomy (group B)

Standard atrial septal anatomy, group A (Fig. 2)

- Typical central ASD location
- Mean gradient <15 mm Hg

Complex atrial septal anatomy, group B (Fig. 3)

- Intact atrial septum (Fig. 3C and E)
- Severely restrictive intraatrial septum (mean Doppler gradient ≥ 15 mm Hg)
- Nontypical ASD location:
 - Superior (close to the pulmonary veins) (Fig. 3A)
 - Inferior (close to AV node) (Fig. 3D)
 - Other unusual ASD location
- Combination of atrial septal aneurysm and tunnel-type PFO (Fig. 3B)
- Very thick intra-atrial septum (Fig. 3F)

Atrial septal interventions performed


Procedures n (%)

Balloon atrial septostomy	52/67 (77.6%)
Static balloon septoplasty	18/67 (26.9%)
Cutting balloon septoplasty	12/67 (17.9%)
RF perforation of intra-atrial septum	08/67 (11.9%)
Stenting of intra-atrial septum	04/67 (5.9%)


10% of patients had restrictive or intact atrial septum
 9% serious adverse events
 25% of minor adverse events
 50% of adverse events in group B
 Reintervention on atrial septum in 20%
 Stage 2 palliation 73% in group A and 57% in group B

Evaluation and management of life-maintaining structures


Arterial duct




**Hypoplastic left heart syndrome
Aortic atresia**



Large in HLHS with aortic atresia





Prognostic features in hypoplastic left heart syndrome

Anatomical & functional factors

1. Right ventricular function
2. Tricuspid valve function
3. Pulmonary valve function
4. Branch pulmonary arteries
5. Ascending aorta
6. Coronary arteries
7. *Associated cardiac malformations*

Non-cardiac modifiers of risk

1. Birth weight
2. Extracardiac anomalies
3. Maternal-fetal environment





Anatomical and functional factors associated with outcomes

- 1.Right ventricular function** needs to be repeatedly evaluated after birth (increased SVR and systemic pressure).
- 2.Tricuspid valve function** may worsen after birth if present in fetus (higher SVR and systemic pressure).
- 3.Ascending aorta
- 4.Coronary arteries
- 5.*Pulmonary valve function*
- 6.*Branch pulmonary arteries*
- 7.*Associated cardiac malformations*

Anatomical and functional factors associated with outcomes

1. **Right ventricular function** needs to be repeatedly evaluated after birth (increased SVR and systemic pressure).
2. **Tricuspid valve function** may worsen after birth if present in fetus (higher SVR and systemic pressure).
3. **Ascending aorta**
4. **Coronary arteries**
5. *Pulmonary valve function*
6. *Branch pulmonary arteries*
7. *Associated cardiac malformations*



Ascending aorta size and outcomes




Anatomical and functional factors associated with outcomes

1. **Right ventricular function** needs to be repeatedly evaluated after birth (increased SVR and systemic pressure).
2. **Tricuspid valve function** may worsen after birth if present in fetus (higher SVR and systemic pressure).
3. **Ascending aorta**
4. **Coronary arteries**
5. *Pulmonary valve function*
6. *Branch pulmonary arteries*
7. *Associated cardiac malformations*




Coronary fistula in HLHS



Coronary fistula in HLHS



Anatomic subtype and mortality



Vida VL, et al. J Thorac Cardiovasc Surg. 2008;135:339-46.

Anatomical and functional factors associated with outcomes

1. **Right ventricular function** needs to be repeatedly evaluated after birth (increased SVR and systemic pressure).
2. **Tricuspid valve function** may worsen after birth if present in fetus (higher SVR and systemic pressure).
3. **Ascending aorta**
4. **Coronary arteries**
5. ***Pulmonary valve function***
6. ***Branch pulmonary arteries***
7. ***Associated cardiac malformations : totally anomalous pulmonary venous drainage***

Non cardiac modifiers of risk in HLHS

Preoperative mortality associated with :

Gestational age < 36 weeks

Low birth weight < 2500 g

Major extracardiac congenital abnormality

Increased mortality after stage 1 palliation

Impaired maternal fetal environment (maternal gestational hypertension, preeclampsia, gestational diabetes, and/or smoking during pregnancy)


Hazard ratios of independent risk factors


1- For early death

- obstructed pulmonary venous return **4.75**
- smaller ascending aorta, per mm **1.23**
- anatomic subtype AA/MA vs. AA/MS **0.84**
- lower socioeconomic status **1.28**

2- For constant phase

- Lower gestational age **1.56**
- Genetic syndrome present **9.34**





Evaluation of anatomical and physiological variants of surgical relevance & Practical informations for per-operative monitoring

1.Aortic arch position and branching

- a.Surgical reconstruction
- b.BT shunt placement
- c.Monitoring

2.Aortic valve patency and aortic arch size


- a.Reconstruction of the aortic arch (patch augmentation, DKK)
- b.Retrograde coarctation (for hybrid procedures)
- c.Coronary perfusion issues

3.*Systemic venous anatomy*


4.Associated cardiac malformations

5.Newborn clinical condition


- a.Stable
- b.Unstable, shock/MOF, systemic hypoperfusion




Single Ventricle Reconstruction trial



1 year



3 years (conditional)




6 years

Term newborns AA RVPAS vs. Preterm newborns AS MBTS


Ohye RG, et al. Comparison of shunt types in the Norwood procedure for single-ventricle lesions. New England Journal of Medicine. 2010;362:1980-92.
Newburger JW, et al. Transplantation-free survival and interventions at 3 years in the single ventricle reconstruction trial. Circulation. 2014;129:2013-20.
Newburger JW, et al. Transplant-Free Survival and Interventions at 6 Years in the SVR Trial. Circulation. 2018;137:2246-2253.

Hypoplastic left heart syndrome





Norwood-Hybrid - *Angiographies after PA banding and ductal stenting*



- 1-Salvation procedure
- 2-Intentional alternative to the Norwood procedure



No Norwood/No hybrid



The plan of action should set the ground for next stage

	Fetus	Neonate
Survival	Termination of pregnancy Planned delivery	Comfort care
Interventions	Aortic valve dilatation Atrial septum opening	Preoperative care Stage 1 palliation Transplantation
Suitability for subsequent stage	NA	Suitability for stage 2

Respective risks of surgical/hybrid approaches
-for interstage re-interventions
-for stage 2 complexity
-for extracardiac risk : neurodevelopment



Stage 1 palliative intent has to be defined

Hybrid as alternative to Norwood

No convincing superiority

Salvage procedure

Procedure to stabilize hemodynamically unstable patients who are otherwise unsuitable for the Norwood operation.

Deferred Norwood

Strategy to utilize the hybrid approach to intentionally defer the Norwood operation for weeks to months. A Norwood is the second planned procedure.


Pretransplantation palliation

Strategy to utilize bilateral pulmonary artery banding to improve hemodynamic stability while awaiting a suitable organ for transplantation.

Univentricular-biventricular


Strategy to promote growth of left ventricular structures to increase probability of achieving a biventricular repair decision deferral typically with deliberate maintenance of a restrictive atrial septum.

Transitioning from the « one-size-fits-all » to « precision medicine » model with multi-level patient stratification



« Stratified medicine » in HLHS before stage 1

Towards precision medicine in HLHS ?



Thank you



Collective ignorance is the motivation
Curiosity is the strength
Research is the path

Individual experience is the brake
Indifference is the weakness
Authority argument is the threat